Creabilis hires chief medical officer

Dr David Roblin joins the firm after holding leading roles at Pfizer and Bayer

Creabilis, a clinical stage European biotechnology company focused on dermatology, inflammation and pain, has appointed David Roblin as chief medical officer.

Roblin has gained extensive experience in the pharmaceutical industry in a career spanning more than 15 years. He has held leadership roles at Pfizer and Bayer across a range of therapy areas in research, development and commercial roles.

At Pfizer, Roblin was most recently senior vice president, head of research and site head for European r&d. Before this, he was head of anti-infectives at Bayer Medical Affairs.

In addition Roblin has chaired the research director’s group of the European Federation of Pharmaceutical Industries and Associations (EFPIA), and was a co-founder of the Innovative Medicines Initiative, a US$2bn public-private partnership with the European Commission.

You may also like

Finance

Creabilis establishes UK operation

Location in Kent broadens the county’s links with the pharma industry
Manufacturing

Thermo Fisher Scientific highlights its new accelerator drug development solutions at CPHI Frankfurt 2025

The company has also announced a collaboration with OpenAI as well as a new digital toolbox, OSDPredict, which combines AI and machine learning models to predict formulation behaviour in small-molecule development
Pharmaceutical

Moderna named a top employer by Science for eleventh consecutive year

Moderna was recognised for its commitment to continuous innovation and a culture that reflects the values of its employees.
Pharmaceutical

Pharma leaders to join together to shape the future of the industry at CPHI Frankfurt Leadership Summit

As the pharmaceutical industry enters a defining period of transformation, Informa Markets is hosting an exclusive Leadership Summit at this year’s CPHI Frankfurt, bringing together some of the sector’s most influential executives to address the challenges and opportunities shaping global healthcare
Pharmaceutical

Takeda and Innovent Biologics partner to advance next-gen oncology medicines

Takeda will establish manufacturing of two next-generation late-stage investigational medicines in the US and will receive exclusive commercialisation rights for IBI363 and IBI343 outside the US and China
Manufacturing

Roquette opens pharmaceutical innovation centre in Brazil

The Health & Pharma Solutions facility in São Paolo offers state-of-the-art laboratories for customers, with the Northeast Center for Strategic Technologies partnering with Roquette to empower young women to pursue careers in science through the Futuras Cientistas programme at the facility
Manufacturing

Samsung Bioepis and Phrontline join forces to advance best-in-class antibody-drug conjugate therapeutics for solid tumours

The pair will co-develop two investigational ADC assets directed against targets expressed in a broad range of cancers, adding a new class of bispecific and dual-payload ADC therapeutics to Samsung Bioepis' oncology portfolio
Subscribe now